VBI Vaccines Inc.

VBI Vaccines Inc.

Driven by Immunology in the Pursuit of Powerful Prevention and Treatment of Disease

Founded 2001

Cambridge, United States 57 employees Post-IPO Equity Total: $186.24M Biotechnology, Health Care

VBI Vaccines Inc. is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, COVID-19, and coronaviruses, and cytomegalovirus (“CMV”), as well as aggressive cancers including glioblastoma (“GBM”). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. Founded in 2001, VBI Vaccines Inc. operates in the Biotechnology and Health Care industries. The company received a $2.00MPost-IPO Equity investment on April 9, 2024. Overall, VBI's focus on leveraging immunology to develop innovative vaccine candidates for a range of diseases, including COVID-19 and various cancers, positions it as a significant player in the biopharmaceutical industry. With its global presence and cutting-edge technology, VBI Vaccines Inc. presents an attractive investment opportunity for venture capital firms seeking to support groundbreaking solutions in the healthcare sector. More information about the company and its latest developments can be found on the official website: www.vbivaccines.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Equity	$2.00M	-		09 Apr 2024
Grant	$84.00M	1	Strategic Innovation Fund	05 Aug 2020
Post IPO Debt	$20.00M	1	K2 HealthVentures	27 May 2020
Post IPO Debt	$13.00M	1	Perceptive Advisors	06 Dec 2016
Post IPO Equity	$10.60M	1	Perceptive Advisors	06 Dec 2016
Post IPO Equity	$6.29M	-		26 Aug 2015
Post IPO Debt	$1.50M	-		25 Mar 2014
Post IPO Debt	$1.38M	-		24 Dec 2013
Post IPO Debt	$250.00K	-		26 Aug 2013
Post IPO Debt	$750.00K	-		10 Jun 2013

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

$2.00M

09 Apr 2024

Grant

$84.00M

Strategic Innovation Fund

05 Aug 2020

Post IPO Debt

$20.00M

K2 HealthVentures

27 May 2020

Post IPO Debt

$13.00M

Perceptive Advisors

06 Dec 2016

Post IPO Equity

$10.60M

Perceptive Advisors

06 Dec 2016

Post IPO Equity

$6.29M

26 Aug 2015

Post IPO Debt

$1.50M

25 Mar 2014

Post IPO Debt

$1.38M

24 Dec 2013

Post IPO Debt

$250.00K

26 Aug 2013

Post IPO Debt

$750.00K

10 Jun 2013

FAQ About VBI Vaccines Inc.

Driven by Immunology in the Pursuit of Powerful Prevention and Treatment of Disease

VBI Vaccines Inc. was founded in 2001.

VBI Vaccines Inc. is headquartered in Cambridge, United States.

VBI Vaccines Inc. operates in Biotechnology and Health Care. Its work centres on biopharmaceutical company, immunology, vaccine development and virus-like particles.

VBI Vaccines Inc. has approximately 57 employees.

VBI Vaccines Inc. has completed 15 funding rounds, raising a total of $186.24M. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to VBI Vaccines Inc. include AdaptVac, 辽宁依生生物制药有限公司, Genelabs Technologies, Osivax, HilleVax. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

VBI Vaccines Inc. and AdaptVac are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About VBI Vaccines Inc.

Funding Rounds & Investors (15)

VBI Vaccines Inc. Alternatives & Competitors

FAQ About VBI Vaccines Inc.